Atopic dermatitis, a chronic inflammatory skin disorder, arises when allergens, such as house dust mites, penetrate a compromised skin barrier, activating pathogenic T cells. Subcutaneous allergen-specific immunotherapy (SIT), involving repeated allergen injections, modulates the immune system by activating regulatory T cells to suppress hypersensitivity reactions.

The researchers isolated and examined regulatory T cells from patients responding to immunotherapy and from mouse models. Their findings revealed that regulatory T cells expressing the transcription factor RORγt are strongly associated with treatment efficacy. These RORγt-expressing cells suppress pathogenic T cell activity and accumulate in the skin, delivering robust anti-inflammatory effects.
“Elucidating the diversity and function of skin immune cells is essential for advancing immune-based therapies,” said Dr. Chang-Wook Park, a professor of dermatology at Severance Hospital. “This study lays the groundwork for enhancing the precision and effectiveness of treatments for atopic dermatitis and other inflammatory skin conditions.”
Health In News Team Lim Hye Jeong
press@hinews.co.kr